Abstract
Early diagnosis and life‐long surveillance are clinically important to improve the long‐term survival of bladder cancer (BCa) patients. Cystoscopy is considered the gold standard for the clinical diagnosis of human BCa. However, it is expensive and invasive. The objective of this study was to discover novel biomarkers to distinguish BCa from healthy controls, urothelium carcinoma and benign bladder lesions by LC‐MS based metabolomics and proteomics. We also tried to differentiate high‐grade and low‐grade BCa. A total of 234 subjects were enrolled, including 80 healthy adults, 22 benign patients, 26 urothelium carcinoma patients and 106 BCa patients (63 high‐grade BCa, 43 low‐grade BCa). The results showed that both urine metabolites and urine proteins could distinguish the BCa group from the healthy group, urothelium carcinoma group and benign bladder lesions group. And the combination of metabolites and proteins could achieve higher accuracy. Similarly, BCa clinical stages (high‐ vs. low‐grade BCa) could be better separated with a panel consisting of metabolites and proteins than either the metabolite panel or the protein panel alone. In conclusion, this study showed that urine proteomic and metabolic profiling were able to assist in the detection of BCa and grading distinguish.Support or Funding InformationNational Basic Research Program of China (No. 2013CB530805, 2014CBA02005)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
